Cargando…
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice
In oncology practices across the United States, biosimilars—highly similar versions of licensed, innovator (reference) biological medicines—are currently emerging as more affordable therapeutic options. Only after a rigorous product development program, during which a proposed biosimilar is analyzed...
Autores principales: | Mayden, Kelley D., Kelton, John M., Ryan, Joanne C., McBride, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214965/ https://www.ncbi.nlm.nih.gov/pubmed/35755898 http://dx.doi.org/10.6004/jadpro.2022.13.4.5 |
Ejemplares similares
-
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015) -
Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017) -
Biosimilars: Beginning a Conversation
por: Campen, Christopher J., et al.
Publicado: (2016) -
Mind-Body Therapies: Evidence and Implications in Advanced Oncology Practice
por: Mayden,, Kelley D.
Publicado: (2012) -
Improving Health Equity: The Role of the Oncology Advanced Practitioner in Managing Implicit Bias
por: Mayden, Kelley D.
Publicado: (2021)